Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Todorova, Valentina K ^a,b   Beggs, Marjorie L ^c,e   Delongchamp, Robert R ^c   Dhakal, Ishwori ^c   Makhoul, Issam ^c   Wei, Jeanne Y ^d   Klimberg, V Suzanne ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Nephropathology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; DOXORUBICIN; JANUS KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RNA; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLU GENE; CONTROLLED STUDY; CTNNA1 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; JAK1 GENE; MICROARRAY ANALYSIS; NFE2L2 GENE; NONHUMAN; NRF2 GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; RAT; RISK ASSESSMENT; S100A8 GENE; TPM3 GENE; UBIQUITINATION; YWHAB GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART; HEART DISEASES; LEUKOCYTES, MONONUCLEAR; LYMPHOPENIA; MOLECULAR SEQUENCE ANNOTATION; MYOCARDIUM; RATS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

RATTUS;

EID: 84870280062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048398     Document Type: Article

References (109)

1. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A, (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10: 337-345.
2. Gharib MI, Burnett AK, (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4: 235-42.
3. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, et al. (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23: 7685-94.
4. Singal PK, Iliskovic N, (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-912.
5. Swain SM, Whaley FS, Ewer MS, (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-79.
6. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA, (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13: 819-29.
7. Shan K, Lincoff AM, Young JB, (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47-58.
8. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE, (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27: 53-68.
9. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, et al. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14: 362-372.
10. Bovelli D, Plataniotis G, Roila F, (2010) ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease. ESMO Clinical Practice Guidelines. Ann Oncol 21: Suppl 5: v277-82.
11. Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, et al. (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11: Suppl 1, S21-36.
12. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE, (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8: 1039-58.
13. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, et al. (2008)Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26: 3777-84.
14. Jain D, (2000) Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 7: 53-68.
15. Swain SM, Whaley FS, Ewer MS, (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869.
16. Pai VB, Nahata MC, (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22: 263-302.
17. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, et al. (2000) It's time for a change to a troponin standard. Circulation 102: 1216-20.
18. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kagiyama K, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203.
19. Herman EH, Lipshultz SE, Ferrans VJ (2003) The use of cardiac biomarkers to detect myocardial damage induced by chemotherapeutic agents. In: Wu AHB, ed. Cardiac Markers. 2nd ed. Totowa, NJ: Humana Press, 87-109.
20. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M, (2008)Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 130: 688-710.
21. Lu P, (2005) Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 35: 197-201.
22. Swain SM, Whaley FS, Ewer MS, (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-79.
23. Elliott P, (2006) Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33: 3 Suppl 8 S2-7.
24. Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE, (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-78.
25. Staratschek-Jox A, Classen S, Gaarz A, Debey-Pascher S, Schultze JL, Blood-based transcriptomics: Leukemias and beyond. Expert Rev Mol Diagn 9 (2009): 271-280.
26. Mohr S, Liew CC, (2007) The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 13: 422.
27. Umbright C, Sellamuth R, Li S, Kashon M, Luster M, et al. (2010) Blood gene expression markers to detect and distinguish target organ toxicity. Mol Cell Biochem 335: 223-234.
28. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA, (2006) The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 147: 126-130.
29. Ikeda Y, Aihara K, Akaike M, Sato T, Ishikawa K, et al. (2010) Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 24: 1338-48.
30. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers (2005) U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) July 2005 Pharmacology and Toxicology.
31. Hayward R, Hydock DS, (2007) Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci 46: 20-32.
32. Medicine and Healthcare products Regulatory Agency website. Available: http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2024436.pdf. Accessed 2012 May 20.
33. Todorova VK, Kaufmann Y, Hennings LJ, Klimberg VS, (2010) Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats. Cancer Chem Pharmacol 66: 315-23.
34. Zhao Y, Wang H, Gustafsson M, Muraro A, Bruhn S, et al. (2012) Combined multivariate and pathway analyses show that allergen-induced gene expression changes in CD4+ T cells are reversed by glucocorticoids. PLoS One 7: e39016.
35. Wright WR, Parzych K, Crawford D, Mein C, Mitchell JA, Paul-Clark MJ, (2012) Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke. PLoS One 7: e30120.
36. Allison DB, Cui X, Page GP, Sabripour M, (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65.
37. Shmookler Reis RJ, Ayyadevara S, Crow WA, Lee T, Delongchamp RR, (2012) Gene categories differentially expressed in C. elegans age-1 mutants of extraordinary longevity: New insights from novel data-mining procedures. J Gerontol A Biol Sci Med Sci 67: 366-75.
38. Delongchamp RR, Velasco C, Dial S, Harris A, (2005) Genome-wide estimation of gender differences in the expression of human liver genes: Statistical design and analysis. BMC Bioinformatics 6: S13.
39. Wright GW, Simon RM, (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448-55.
40. Efron B, (2004) Large-Scale Simultaneous Hypothesis Testing: The Choice of a Null Hypothesis. JASA 99: 96-104.
41. Storey JD, (2002) A direct approach to false discovery rates. J Roy Stat Soc B 64: 479-98.
42. Delongchamp R, Lee T, Velasco C, (2006) A method for computing the overall statistical significance of a treatment effect among a group of genes. BMC Bioinformatics 7: Suppl2 S11.
43. Lee T, Desai VG, Velasco C, Shmookler Reis RJ, Delongchamp RR, (2008)Testing for treatment effects on gene ontology. BMC Bioinformatics 9: Suppl 9, S20.
44. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289-300.
45. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
46. Delongchamp RR, Bowyer JF, Chen JJ, Kodell RL, (2004) Multiple-testing strategy for analyzing cDNA array data on gene expression. Biometrics 60: 774-82.
47. Schweder T, Spjotvoll E, (1982) Plots of p-values to evaluate many tests simultaneously. Biometrika 69: 493-502.
48. Islam KN, Koch WJ, (2012) Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J Biol Chem 287: 12771-8.
49. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, et al. (2001) Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98: 6668-73.
50. Hikoso S, Yamaguchi O, Nakano Y, Takeda T, Omiya S, et al. (2009) The I{kappa}B kinase {beta}/nuclear factor {kappa}B signaling pathway protects the heart from hemodynamic stress mediated by the regulation of manganese superoxide dismutase expression. Circ Res 105: 70-9.
51. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, et al. (2007) Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104: 14074-9.
52. Golden HB, Watson LE, Lal H, Verma SK, Foster DM, et al. (2009) Anthrax toxin: pathologic effects on the cardiovascular system. Front Biosci 14: 2335-57.
53. Nguyen T, Nioi P, Pickett CB, (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-5.
54. Zhang DD, (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38: 769-789.
55. Motohashi H, Yamamoto M, (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10: 549-557.
56. Hayes JD, McMahon M, (2001) Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett 174: 103-113.
57. Kensler TW, Wakabayashi N, Biswal S, (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116.
58. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, et al. (2002) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243.
59. Sekhar KR, Yan XX, Freeman L, (2002) Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene 21: 6829-6834.
60. Jesenberger V, Jentsch S, (2002) Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3: 112-21.
61. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
62. Wójcik C, (2002) Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med 6: 25-48.
63. Kumarapeli AR, Horak KM, Glasford JW, Li J, Chen Q, et al. (2005) A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J 19: 2051-3.
64. Deane JA, Fruman DA, (2004) Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 22: 563-598.
65. Underhill DM, Ozinsky A, (2002) Phagocytosis of microbes: complexity in action. Annu. Rev Immunol 20: 825-852.
66. Merten KE, Jiang Y, Feng W, Kang YJ, (2006) Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J Pharmacol Exp Ther 319: 934-40.
67. Wei JY, (1995) Cardiovascular comorbidity in the older cancer patients. Seminars in Oncol 22: 9-10.
68. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
69. Zhang YW, Shi J, Li YJ, Wei L, (2009) Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 57: 435-45.
70. Toth A, Nickson P, Qin LL, Erhardt P, (2006) Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase. J Biol Chem 281: 3679-89.
71. Golden HB, Watson LE, Lal H, Verma SK, Foster DM, et al. (2009) Anthrax toxin: pathologic effects on the cardiovascular system. Front Biosci 14: 2335-57.
72. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-88.
73. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-78.
74. Mora A, Davies AM, Bertrand L, Sharif I, Budas GR, et al. (2003) Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J 22: 4666-76.
75. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, et al. (2003) Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 111: 1475-86.
76. Bueno OF, De Windt LJ, Lim HW, Tymitz KM, Witt SA, et al. (2001) The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88: 88-96.
77. Infanger DW, Sharma RV, Davisson RL, (2006) NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 8: 1583-96.
78. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, et al. (2009) Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin. Hypertension 54: 338-44.
79. Li H, Gao Y, Qi Y, Katovich MJ, Jiang N, et al. (2008)Macrophage migration inhibitory factor in hypothalamic paraventricular nucleus neurons decreases blood pressure in spontaneously hypertensive rats. FASEB J 22 (2008): 3175-85.
80. Wang Y, (2007) Mitogen-activated protein kinases in heart development and diseases. Circulation 116: 1413-23.
81. Sheikh F, Chen Y, Chen Y, Liang X, Hirschy A, et al. (2006) alpha-E-catenin inactivation disrupts the cardiomyocyte adherens junction, resulting in cardiomyopathy and susceptibility to wall rupture. Circulation 114: 1046-55.
82. Purcell NH, Darwis D, Bueno OF, Müller JM, Schüle R, et al. (2004) Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 24: 1081-95.
83. Gooch JL, (2006) An emerging role for calcineurin Aalpha in the development and function of the kidney. Am J Physiol Renal Physiol 290: F769-76.
84. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, et al. (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol 30: 1415-21.
85. Ghosh P, Dahms NM, Kornfeld S, (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4: 202-12.
86. Croce K, (2010) S100A8/A9 complex: more than just a biomarker of cardiovascular risk? Circ J 74: 626-627.
87. Perera C, McNeil HP, Geczy CL, (2010) S100 Calgranulins in inflammatory arthritis. Immunol Cell Biolm 88: 41-49.
88. Nacken W, Roth J, Sorg C, Kerkhoff C, (2003) S100A9: a myeloid S100 representative as a prominent player in innate immunity. Microsc Res Tech 60: 569-580.
89. Todorova VK, Kaufmann Y, Hennings LJ, Klimberg VS, (2010) Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats. Cancer Chem Pharmacol 66: 315-23.
90. Todorova V, Kaufmann Y, Hennings L, Klimberg S, (2009) Protective effects of glutamine against acute doxorubicin cardiotoxicity in tumor-bearing rats. J Nutr 140: 44-8.
91. Herman EH, (1998) Ferrans VJ, (1998) Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 25: 15-21.
92. Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA, et al. (2001) Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 8: 1649-60.
93. Wallace KB, (2003) Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93: 105-15.
94. Shi Y, Moon M, Dawood S, McManus B, Liu PP, (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36: 296-305.
95. Harvey RA, Champe PC (eds) (1992) Anticancer drugs, in Lippincott's Illustrated Reviews: Pharmacology. Philadelphia, JB Lippincott Company.
96. Hershman DL, Shao T, (2009) Anthracycline cardiotoxicity after breast cancer treatment. Oncology 23: 1-15.
97. Singal PK, Iliskovic N, (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905.
98. Shi Y, Moon M, Dawood S, McManus B, Liu PP, (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36: 296-305.
99. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, et al. (2006) Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 290: H1098-102.
100. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
101. Kresh JY, Chopra A, (2011) Intercellular and extracellular mechanotransduction in cardiac myocytes. Pflugers Arch 462: 75-87.
102. Vanburen P, Ma J, Chao S, Mueller E, Schneider DJ, et al. (2011) Blood gene expression signatures associate with heart failure outcomes. Physiol Genomics 43: 392-7.
103. Averill MM, Kerkhoff C, Bornfeldt KE, (2012) S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 32: 223-9.
104. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, et al. (2006) Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 113: 2278-2284.
105. Altwegg LA, Neidhart M, Hersberger M, Müller S, Eberli FR, et al. (2007) Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 28: 941-948.
106. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR, (2008) S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102: 1239-1246.
107. Croce K, Gao H, Wang Y, Mooroka T, Sakuma M, et al. (2009) Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 120: 427-436.
108. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, et al. (2006) Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 290: H1098-102.
109. Berthiaume JM, Wallace KB, (2007) Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment. Cardiovasc Toxicol 7: 178-86.